Akari Therapeutics, Plc announced on October 15, 2024, that the U.S. Securities and Exchange Commission (SEC) declared its Form S-4 registration statement effective on October 11, 2024. This filing is related to the proposed merger between Akari Therapeutics and Peak Bio, Inc.
The effectiveness of the Form S-4 is a crucial regulatory step, allowing Akari to proceed with its plans for the business combination. Following this development, the company has definitively scheduled a General Meeting for its shareholders on November 7, 2024.
Shareholder approval at this upcoming meeting is required for the issuance of shares in connection with the proposed merger. This marks a significant progression towards the finalization of the strategic transaction that aims to broaden Akari's therapeutic focus.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.